AIM ImmunoTech Inc
AIM1.440USD
+0.079+5.83%
收盤 12/19, 16:00（美東）報價延遲15分鐘
3.98M總市值
虧損本益比TTM
關於 AIM ImmunoTech Inc 公司
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
AIM ImmunoTech Inc簡介
公司代碼AIM
公司名稱AIM ImmunoTech Inc
上市日期Jul 12, 1996
CEOEquels (Thomas K)
員工數量21
證券類型Ordinary Share
年結日Jul 12
公司地址2117 Sw Highway 484
城市OCALA
上市交易所NASDAQ OMX – NASDAQ Basic Amex
國家United States of America
郵編32801
電話13524487797
網址https://aimimmuno.com/
公司代碼AIM
上市日期Jul 12, 1996
CEOEquels (Thomas K)
AIM ImmunoTech Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
38.87K
-0.04%
Mr. Ted D. Kellner
Mr. Ted D. Kellner
Independent Director
Independent Director
19.70K
+196850.00%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
-0.08%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
-0.03%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
641.00
-0.16%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
38.87K
-0.04%
Mr. Ted D. Kellner
Mr. Ted D. Kellner
Independent Director
Independent Director
19.70K
+196850.00%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
-0.08%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
-0.03%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
641.00
-0.16%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月16日 週日
更新時間: 11月16日 週日
持股股東
股東類型
持股股東
持股股東
佔比
DRW Securities, LLC
1.52%
Equels (Thomas K)
1.36%
Kellner (Theodore D)
1.30%
Sabby Management, LLC
1.01%
The Vanguard Group, Inc.
0.61%
其他
94.19%
持股股東
持股股東
佔比
DRW Securities, LLC
1.52%
Equels (Thomas K)
1.36%
Kellner (Theodore D)
1.30%
Sabby Management, LLC
1.01%
The Vanguard Group, Inc.
0.61%
其他
94.19%
股東類型
持股股東
佔比
Individual Investor
3.85%
Investment Advisor
2.18%
Investment Advisor/Hedge Fund
1.58%
其他
92.39%
機構持股
更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
56
107.25K
2.64%
--
2025Q3
59
107.25K
2.79%
+95.13K
2025Q2
58
12.12K
12.55%
-36.20K
2025Q1
67
48.31K
13.00%
-45.65K
2024Q4
64
46.48K
14.87%
-43.65K
2024Q3
61
90.13K
15.18%
+5.69K
2024Q2
61
84.44K
8.12%
+43.50K
2024Q1
64
40.95K
9.51%
-6.49K
2023Q4
65
41.55K
9.71%
-1.72K
2023Q3
69
43.37K
10.32%
-1.62K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Equels (Thomas K)
38.88K
1.44%
+210.00
+0.54%
Jun 13, 2025
Kellner (Theodore D)
19.70K
0.73%
+19.68K
+196850.00%
Apr 11, 2025
Deutsch (Todd A)
17.16K
0.63%
--
--
Dec 19, 2024
Mitchell (William M)
5.22K
0.19%
+1.97K
+60.53%
Apr 11, 2025
Rodino (Peter W III)
4.02K
0.15%
+5.00
+0.12%
Apr 04, 2025
Appelrouth (Stewart L.)
3.89K
0.14%
+670.00
+20.82%
Dec 31, 2024
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Mar 03, 2025
Merger
100→1
公告日期
類型
比率
Mar 03, 2025
Merger
100→1
常見問題
AIM ImmunoTech Inc的前五大股東是誰？
AIM ImmunoTech Inc的前五大股東如下：
Equels (Thomas K)持有股份：38.88K佔總股份比例：1.44%。
Kellner (Theodore D)持有股份：19.70K佔總股份比例：0.73%。
Deutsch (Todd A)持有股份：17.16K佔總股份比例：0.63%。
Mitchell (William M)持有股份：5.22K佔總股份比例：0.19%。
Rodino (Peter W III)持有股份：4.02K佔總股份比例：0.15%。
Equels (Thomas K)持有股份：38.88K佔總股份比例：1.44%。
Kellner (Theodore D)持有股份：19.70K佔總股份比例：0.73%。
Deutsch (Todd A)持有股份：17.16K佔總股份比例：0.63%。
Mitchell (William M)持有股份：5.22K佔總股份比例：0.19%。
Rodino (Peter W III)持有股份：4.02K佔總股份比例：0.15%。
AIM ImmunoTech Inc的前三大股東類型是什麼？
AIM ImmunoTech Inc 的前三大股東類型分別是：
DRW Securities, LLC
Equels (Thomas K)
Kellner (Theodore D)
DRW Securities, LLC
Equels (Thomas K)
Kellner (Theodore D)
有多少機構持有AIM ImmunoTech Inc(AIM)的股份？
截至2025Q4，共有56家機構持有AIM ImmunoTech Inc的股份，合計持有的股份價值約為107.25K，占公司總股份的2.64% 。與2025Q3相比，機構持股有所增加，增幅為-0.15%。
哪個業務部門對AIM ImmunoTech Inc的收入貢獻最大？
在--，--業務部門對AIM ImmunoTech Inc的收入貢獻最大，創收--，占總收入的--% 。
